Abstract
Several microRNAs (miRNAs) have been implicated in the pathophysiology of pulmonary fibrosis; however, the detailed mechanisms remain unclear. miR-26a has demonstrated antifibrotic effects, particularly when its expression is suppressed in the airways. However, the effects of systemic miR-26a deficiency on pulmonary fibrosis have not been investigated. We found that miR-26a knockout (KO) mice exhibited reduced pulmonary fibrosis compared with wild-type (WT) mice. Whole-lung RNA sequencing analysis indicated that the mammalian target of rapamycin complex 1 (MTORC1) signaling and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathways were elevated in the WT group compared with the KO group. Loss of miR-26a increases PTEN expression, a target gene of miR-26a, resulting in the reduction of Timp1 levels downstream of the PI3K/Akt-mTOR pathway, thereby attenuating fibrosis. Transfection with miR-26a significantly suppressed Pten expression and increased Timp1 and Acta2 expression in primary lung fibroblasts in vitro. These results are consistent with the in vivo findings, which suggest that miR-26a promotes fibrosis, contrary to previous reports indicating an antifibrotic role for miR-26a. Our findings suggest that local and systemic inhibition of miR-26a may exert opposing effects, highlighting the importance of careful interpretation of miR-26a-targeted therapeutic strategies.